User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 9 results.
    • Journal article
    Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy
    Van Cutsem, Eric Joulain, Florence Hoff, Paulo M Mitchell, Edith Ruff, Paul Lakomý, Radek Prausová, Jana Moiseyenko, Vladimir M van Hazel, Guy Cunningham, David Arnold, Dirk Schmoll, Hans-Joachim Ten Tije, Albert J McKendrick, Joseph Kröning, Hendrik Humblet, Yves[UCL] Grávalos, Cristina Le-Guennec, Solenn Andria, Michael Dochy, Emmanuelle Vishwanath, Raghu L Macarulla, Teresa Tabernero, Josep (2016) Targeted Oncology : biotherapies for the clinicians in oncology — Vol. 11, no. 3, p. 383-400 (2016)
    • Journal article
    Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.
    Ajani, Jaffer El Hajbi, Farid Cunningham, David Alsina, Maria Thuss-Patience, Peter Scagliotti, Giorgio V Van den Eynde, Marc[UCL] Kim, Sung-Bae Kato, Ken Shen, Lin Li, Liyun Ding, Ningning Shi, Jingwen Barnes, Gisoo Van Cutsem, Eric (2024) ESMO open — Vol. 9, no.1, p. 102202 [1-9] (2024)
    • Speech
    Panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment for metastatic colorectal cancer (mCRC): results from the randomised phase III PRIME study
    Siena, Salvatore Douillard, Jean-Yves Tabernero, Josef Cassidy, James Burkes, Ronald Barugel, Mario E. Humblet, Yves[UCL] Cunningham, David Wolf, Michael Gansert, Jennifer (2010) —
    • Journal article
    Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
    Douillard, Jean-Yves Oliner, Kelly S Siena, Salvatore Tabernero, Josep Burkes, Ronald Barugel, Mario Humblet, Yves[UCL] Bodoky, Gyorgy Cunningham, David Jassem, Jacek Rivera, Fernando Kocákova, Ilona Ruff, Paul Błasińska-Morawiec, Maria Šmakal, Martin Canon, Jean Luc Rother, Mark Williams, Richard Rong, Alan Wiezorek, Jeffrey Sidhu, Roger Patterson, Scott D (2013) New England Journal of Medicine — Vol. 369, no.11, p. 1023-1034 (2013)
    • Journal article
    On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
    Morschhauser, Franck Machiels, Jean-Pascal[UCL] Salles, Gilles Rottey, Sylvie Rule, Simon Aj Cunningham, David Peyrade, Frederic Fruchart, Christophe Arkenau, Hendrik-Tobias Genvresse, Isabelle Liu, Li Köchert, Karl Shen, Kui Kneip, Christoph Peña, Carol E Grevel, Joachim Zhang, Jun Cisternas, Galia Reschke, Susanne Granvil, Camille Awada, Ahmad (2020) Molecular cancer therapeutics — Vol. 19, no. 2, p. 468-478 (2020)
    • Speech
    Prime study : a randomised phase 3 study of panitumumab with Folfox4 versus Folfox4 alone as first line treatment for metastatic colorectal cancer (mCRC)
    Siena, Salvatore Douillard, Jean-Yves Tabernero, Josef Cassidy, James Burkes, Ronald Barugel, Mario E. Humblet, Yves[UCL] Cunningham, David Wolf, Michael Gansert, Jennifer (2010) European Multidisciplinary Colorectal Cancer Congress — (France)Nice
    • Journal article
    The iR regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
    Ramchandren, Radhakrishnan Johnson, Peter Ghosh, Nilanjan Ruan, Jia Ardeshna, Kirit M Johnson, Roderick Verhoef, Gregor Cunningham, David de Vos, Sven Kassam, Shireen Fayad, Luis Radford, John Bailly, Sarah[UCL] Offner, Fritz Morgan, David Munoz, Javier Ping, Jerry Szafer-Glusman, Edith Eckert, Karl Neuenburg, Jutta K Goy, Andre (2023) EClinicalMedicine — Vol. 56, p. 101779 [1-15] (2023)
    • Speech
    Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1(st)-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial
    Douillard, Jean-Yves Siena, Salvatore Cassidy, James Tabernero, Josef Burkes, Ronald Barugel, Mario E. Humblet, Yves[UCL] Cunningham, David Wolf, Michael Gansert, Jennifer L. (2009) 15th ECCO/34th ESMO Multidisciplinary Congress — (Germany) Berlin
    • Journal article
    Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer : the PRIME study
    Douillard, Jean-Yves Siena, Salvatore Cassidy, James Tabernero, Josep Burkes, Ronald Barugel, Mario Humblet, Yves[UCL] Bodoky, György Cunningham, David Jassem, Jacek Rivera, Fernando Kocákova, Ilona Ruff, Paul Błasińska-Morawiec, Maria Šmakal, Martin Canon, Jean-Luc Rother, Mark Oliner, Kelly S Wolf, Michael Gansert, Jennifer (2010) Journal of Clinical Oncology — Vol. 28, no. 31, p. 4697-4705 (2010)